Amanda M. Vanderplow

Amanda M. Vanderplow

Auto-generated profile, based on publicly available information

Amanda M. Vanderplow

Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, Illinois

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EKElizabeth A. Kiernan
Elizabeth A. Kiernan
TWTao Wang
Tao Wang
AVAmanda M. Vanderplow
Amanda M. Vanderplow
SCSneha Cherukuri
Sneha Cherukuri
MCMichael E. Cahill
Michael E. Cahill
Jyoti J WattersJyoti J Watters
Jyoti J Watters
Sleep disordered breathing (SDB) affects 3–5% of the pediatric population, including neonates who are highly susceptible due to an underdeveloped ventilatory control system, and REM-dominated sleep. Although pediatric SDB is associated with poor cognitive outcomes, very little research has focused on models of pediatric SDB, particularly in neonates. In adults and neonates, intermittent hypoxia (IH), a hallmark of SDB, recapitulates multiple physiological aspects of severe SDB, including neuronal apoptosis, sex-specific cognitive deficits, and neuroinflammation. Microglia, resident CNS immune cells, are important mediators of neurodevelopment and neuroinflammation, but to date, no studies have examined the molecular properties of microglia in the context of neonatal IH. Here, we tested the hypothesis that neonatal IH will enhance microglial inflammation and sex-specifically lead to long-term changes in working memory. To test this hypothesis, we exposed post-natal day (P1) neonates with dams to an established adult model of pathological IH consisting of 2 min cycles of 10.5% O2 followed by 21% O2, 8 h/day for 8 days. We then challenged the offspring with bacterial lipopolysaccharide (LPS) at P9 or at 6–8 weeks of age and immunomagnetically isolated microglia for gene expression analyses and RNA-sequencing. We also characterized neonatal CNS myeloid cell populations by flow cytometry analyses. Lastly, we examined working memory performance using a Y-maze in the young adults. Contrary to our hypothesis, we found that neonatal IH acutely augmented basal levels of microglial anti-inflammatory cytokines, attenuated microglial responses to LPS, and sex-specifically altered CNS myeloid populations. We identified multiple sex differences in basal neonatal microglial expression of genes related to chemotaxis, cognition, and aging. Lastly, we found that basal, but not LPS-induced, anti-inflammatory cytokines were augmented sex-specifically in the young adults, and that there was a significant interaction between sex and IH on basal working memory. Our results support the idea that neonates may be able to adapt to IH exposures that are pathological in adults. Further, they suggest that male and female microglial responses to IH are sex-specific, and that these sex differences in basal microglial gene expression may contribute to sexual dimorphisms in vulnerability to IH-induced cognitive disruption.

8 October 2024 in RNA
Verified
Journal Article
Open access
PDF file
AVAmanda M. Vanderplow
Amanda M. Vanderplow
GDGrace E. Dodis
Grace E. Dodis
YRYewon Rhee
Yewon Rhee
JCJakub J. Cikowski
Jakub J. Cikowski
SGSonia Gonzalez
Sonia Gonzalez
RGRocco G. Gogliotti
Rocco G. Gogliotti
Rett syndrome (RTT) is a neurodevelopmental disorder caused by loss-of-function mutations in themethyl-CpG-binding protein 2(MECP2) gene. Despite its severe phenotypes, studies in mouse models suggest that restoring MeCP2 levels can reverse RTT symptomology. Nevertheless, traditional gene therapy approaches are hindered by MeCP2's narrow therapeutic window, complicating the safe delivery of viral constructs without overshooting the threshold for toxicity. The 3′ untranslated region (3′ UTR) plays a key role in gene regulation, where factors like miRNAs bind to pre-mRNA and fine-tune expression. Given that each miRNA's contribution is modest, blocking miRNA binding may represent a potential therapeutic strategy for diseases with high dosage sensitivity, like RTT. Here, we present a series of site-blocking antisense oligonucleotides (sbASOs) designed to outcompete repressive miRNA binding at theMECP23′ UTR. This strategy aims to increase MeCP2 levels in patients with missense or late-truncating mutations, where the hypomorphic nature of the protein can be offset by enhanced abundance. Our results demonstrate that sbASOs can elevate MeCP2 levels in a dose-dependent manner in SH-SY5Y and patient fibroblast cell lines, plateauing at levels projected to be safe. Confirming in vivo functionality, sbASO administration in wild-type mice led to significant Mecp2 upregulation and the emergence of phenotypes associated with Mecp2 overexpression. In a T158M neural stem cell model of RTT, sbASO treatment significantly increased MeCP2 expression and levels of the downstream effector protein brain-derived neurotrophic factor (BDNF). These findings highlight the potential of sbASO-based therapies for MeCP2-related disorders and advocate for their continued development.

11 April 2019 in Cerebral Cortex
Verified
Journal Article
Closed access
BKBailey A Kermath
Bailey A Kermath
AVAmanda M Vanderplow
Amanda M Vanderplow
MCMichael Cahill
Michael Cahill
While research has identified alterations in dorsolateral prefrontal cortical function as a key factor to the etiology of bipolar disorder, few studies have uncovered robust changes in protein signal transduction pathways in this disorder. Given the direct relevance of protein-based expressional alterations to cellular functions and because many of the key regulatory mechanisms for the disease pathogenesis likely include alterations in protein activity rather than changes in expression alone, the identification of alterations in discrete signal transduction pathways in bipolar disorder would have broad implications for understanding the disease pathophysiology. As prior microarray data point to a previously unrecognized involvement of the RhoA network in bipolar disorder, here we investigate the protein expression and activity of key components of a RhoA signal transduction pathway in dorsolateral prefrontal cortical homogenates from subjects with bipolar disorder. The results of this investigation implicate overactivation of prefrontal cortical RhoA signaling in specific subtypes of bipolar disorder. The specificity of these findings is demonstrated by a lack of comparable changes in schizophrenia; however, our findings do identify convergence between both disorders at the level of activity-mediated actin cytoskeletal regulation. These findings have implications for understanding the altered cortical synaptic connectivity of bipolar disorder.

18 June 2026 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
SGSonia Gonzalez
Sonia Gonzalez
AVAmanda M. Vanderplow
Amanda M. Vanderplow
TWTheresa R. Wilsterman
Theresa R. Wilsterman
MSMatthew P. Stratton
Matthew P. Stratton
MSMackenzie L. Smith
Mackenzie L. Smith
RGRocco G. Gogliotti
Rocco G. Gogliotti
Rett syndrome (RTT) is a neurodevelopmental disorder that is associated with loss-of-function mutations in the methyl CpG binding protein 2 (MECP2) gene. MECP2 regulates transcription both locally and globally, making it challenging to distinguish between genes that are pathogenic and those that constitute transcriptional noise. A rare subpopulation of patients lack MECP2 mutations despite presenting with sufficient symptoms to warrant a clinical diagnosis of RTT. These patients are classified as having atypical and MECP2 mutation-negative forms of the disorder. We hypothesized that identifying pathways with conserved disruption between typical and atypical forms of RTT would be a viable mechanism to reduce transcriptional noise and identify the genes that are most critical to their shared clinical presentation. To test this theory, we conducted differential RNA sequencing using 5 atypical RTT, 6 typical RTT (R255X), and 9 neurotypical control temporal cortex autopsy samples. Pathways associated with heat shock factor 1 (HSF1) signaling were among the most enriched in both RTT populations. Validation studies using 37 patient temporal cortex samples showed that increased HSF1 signaling was enriched in those with classically severe MECP2 mutations. To investigate whether increased HSF1 signaling is compensatory or pathogenic, we conducted in vivo hyperthermia experiments complemented by cellular stress array analyses. These experiments established that RTT model mice exhibit faster and larger induction of cellular stress-associated proteins. Pharmacological induction of HSF1 in Mecp2+/- mice was consistent with hyperthermia experiments, showing seizure-like phenotypes and lethality. Conversely, chronic inhibition of HSF1 signaling improved RTT-like phenotypes in domains of motor learning and general health. Together, these data suggest that promiscuous HSF1 signaling is likely a pathogenic amplifier of severe phenotypes and provide a rationale that inhibiting this pathology may hold therapeutic potential in RTT and related disorders. SIGNIFICANCE STATEMENT: Rett syndrome is a devastating neurodevelopmental disorder with limited therapeutic options. This manuscript identifies heat shock factor 1-signaling as a novel therapeutic target and proposes a molecular mechanism by which cellular stress responses are regulated in Rett syndrome.